UBS ASSET MANAGEMENT AMERICAS LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 26 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$198,5000.0%200,0000.0%0.00%
Q1 2023$198,500
+1.5%
200,0000.0%0.00%
Q4 2022$195,641
-99.9%
200,0000.0%0.00%
Q3 2022$192,830,000
-36.9%
200,000
-37.9%
0.00%
Q1 2022$305,476,000
-0.3%
322,0000.0%0.00%
Q4 2021$306,274,000
-35.1%
322,000
-38.3%
0.00%
Q3 2021$472,052,000
-98.5%
522,000
-98.5%
0.00%
-100.0%
Q2 2021$31,606,260,000
+9.5%
35,000,0000.0%0.01%
+7.7%
Q1 2021$28,860,650,000
+4.6%
35,000,0000.0%0.01%0.0%
Q4 2020$27,598,900,000
+7.2%
35,000,000
+9.4%
0.01%
-7.1%
Q3 2020$25,745,920,000
-31.0%
32,000,000
-36.0%
0.01%
-39.1%
Q2 2020$37,300,000,000
-11.9%
50,000,000
-4.8%
0.02%
-23.3%
Q1 2020$42,323,295,000
+31.4%
52,500,000
+64.1%
0.03%
+50.0%
Q4 2019$32,209,920,000
+289011.6%
32,000,000
+156.0%
0.02%
+66.7%
Q4 2016$11,141,000
-75.5%
12,500,000
-69.1%
0.01%
-75.5%
Q3 2016$45,425,00040,500,0000.05%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders